We then used the Cancer Cell Line Encyclopedia and Genomics of Drug Sensitivity in Cancer databases to analyze the correlation between HOXB5 gene expression and bortezomib, the clinically approved agent for multiple myeloma with activity to inhibit the NF-κB pathway (Shahshahan et al., 2011). Here, NFKB1 is linked to plasma cell myeloma.